{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:38:55Z","timestamp":1791160735520,"version":"4.1.0"},"reference-count":30,"publisher":"FapUNIFESP (SciELO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["An. Acad. Bras. Ci\u00eanc."],"published-print":{"date-parts":[[2007,9]]},"abstract":"<jats:p>The purpose of this study was to evaluate the effects of the use of the subconjunctival injection of bevacizumab (Avastin\u00ae) on angiogenesis in the rat cornea. Corneas of 20 Wistar male rats were cauterized with silver nitrate crystal. Animals were divided in four groups: control group (GC) that received subconjunctivally 0.02 ml of 0.9% saline solution on the day of the lesion; group GO that received subconjunctivally 0.02 ml of bevacizumab just after the lesion; group G3 that received bevacizumab on day 3 and group G5 that received bevacizumab on day 5 after lesion. Animals were euthanized on day 7. The newly formed vessels were quantified after China Ink perfusion and photographs were obtained and analyzed in a computerized system (Image Pro-Plus\u00ae). In the control group, neovascularization covered 53.56% \u00b1 15.11 (mean \u00b1 SD) of the corneal surface, compared with 35.57% \u00b1 18.80 (mean \u00b1 SD) in the G0 group, 30.60%\u00b111.82 (mean\u00b1SD) in the G3 and 35.86%\u00b10.07 (mean\u00b1SD) in the G5. The results showed an inhibition of angiogenesis when the control group was compared with all treated groups. These results suggest that subconjunctival injection of bevacizumab is able to inhibit corneal angiogenesis independently of the day of treatment.<\/jats:p>","DOI":"10.1590\/s0001-37652007000300004","type":"journal-article","created":{"date-parts":[[2007,10,4]],"date-time":"2007-10-04T12:55:31Z","timestamp":1191502531000},"page":"389-394","source":"Crossref","is-referenced-by-count":49,"title":["The effects of the subconjunctival injection of bevacizumab (Avastin\u00ae) on angiogenesis in the rat cornea"],"prefix":"10.1590","volume":"79","author":[{"given":"Luiz F.M.","family":"Barros","sequence":"first","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rubens","family":"Belfort-Jr","sequence":"additional","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo, Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/00006982-200603000-00016","article-title":"Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment","volume":"26","author":"AVERY RL","year":"2006","journal-title":"Retina","ISSN":"https:\/\/id.crossref.org\/issn\/0275-004X","issn-type":"print"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ophtha.2005.11.019","article-title":"Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration","volume":"113","author":"AVERY RL","year":"2006","journal-title":"Ophthalmology","ISSN":"https:\/\/id.crossref.org\/issn\/0161-6420","issn-type":"print"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/j.ophtha.2006.05.064","article-title":"Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy","volume":"113","author":"AVERY RL","year":"2006","journal-title":"Ophthalmology","ISSN":"https:\/\/id.crossref.org\/issn\/0161-6420","issn-type":"print"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.exer.2004.04.008","article-title":"Effect of COX inhibitors on VEGF-induced retinal vascular leakage and experimental corneal and choroidal neovascularization","volume":"79","author":"CASTRO MR","year":"2004","journal-title":"Exp Eye Res","ISSN":"https:\/\/id.crossref.org\/issn\/0014-4835","issn-type":"print"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/00055735-200108000-00002","article-title":"Corneal neovascularization","volume":"12","author":"CHANG JH","year":"2001","journal-title":"Curr Opin Ophthalmol","ISSN":"https:\/\/id.crossref.org\/issn\/1040-8738","issn-type":"print"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1002\/art.10546","article-title":"Inhibition of interleukin-1 butnot tumor necrosis factor suppresses neovascularization in rat models of corneal angiogenesis and adjuvant arthritis","volume":"46","author":"COXON A","year":"2002","journal-title":"Arthritis Rheum","ISSN":"https:\/\/id.crossref.org\/issn\/0004-3591","issn-type":"print"},{"key":"ref7","first-page":"1112","article-title":"Correlation of VEGF expression by leukocytes with the growth and regression of blood vessels in the rat cornea","volume":"40","author":"EDELMAN JL","year":"1999","journal-title":"Invest Ophthalmol Vis Sci","ISSN":"https:\/\/id.crossref.org\/issn\/0146-0404","issn-type":"print"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"s50","DOI":"10.1007\/s10151-004-0110-4","article-title":"Anti-VEGF antibody bevacizumab (Avastin) with 5FU\/LV as third line treatment for colorectal cancer","volume":"8","author":"EMMANOUILIDES C","year":"2004","journal-title":"Tech Coloproctol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1097\/01.iae.0000230717.85319.f5","article-title":"Safety of intravitreal injection of bevacizumab in rabbit's eye","volume":"26","author":"FEINER L","year":"2006","journal-title":"Retina","ISSN":"https:\/\/id.crossref.org\/issn\/0275-004X","issn-type":"print"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1600-0420.2004.00312.x","article-title":"Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing","volume":"82","author":"GAN L","year":"2004","journal-title":"Acta Ophthalmol Scand","ISSN":"https:\/\/id.crossref.org\/issn\/1395-3907","issn-type":"print"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1159\/000267166","article-title":"Quantification of angiogenesis due to basic fibroblast growth factor in a modified rabbit corneal model","volume":"24","author":"GGAUDRIC A","year":"1992","journal-title":"Ophthalmic Res","ISSN":"https:\/\/id.crossref.org\/issn\/0030-3747","issn-type":"print"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1056\/NEJMoa042760","article-title":"Pegaptanib for neovascular age-related macular degeneration","volume":"351","author":"GRAGOUDAS ES","year":"2004","journal-title":"N Engl J Med","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.ophtha.2005.10.052","article-title":"Ranibizumab for treatment of neovascular age-related macular degeneration","volume":"113","author":"HEIER JS","year":"2006","journal-title":"Ophthalmology","ISSN":"https:\/\/id.crossref.org\/issn\/0161-6420","issn-type":"print"},{"key":"ref14","series-title":"Intrastromal Injection of Bevacizumab (Avastin) for Treatment of Corneal Neovascularization","author":"H\u00d6FLING-LIMA AL","year":"2006"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.mehy.2006.06.063","article-title":"Potential therapeutic strategy for inhibition of corneal neovascularization with new anti-VEGF agents","volume":"68","author":"HOSSEINI H AND NEJABAT MA","year":"2007","journal-title":"Med Hypotheses","ISSN":"https:\/\/id.crossref.org\/issn\/0306-9877","issn-type":"print"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"HURWITZ H ET AL","year":"2004","journal-title":"N Engl J Med","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1200\/JCO.2003.10.066","article-title":"Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)\/Leucovorin (LV) with FU\/LV alone in patients with metastatic colorectal cancer","volume":"21","author":"KABBINAVAR FI","year":"2003","journal-title":"J Clin Oncol","ISSN":"https:\/\/id.crossref.org\/issn\/0732-183X","issn-type":"print"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3928\/1542-8877-20060301-11","article-title":"Intravitreal bevacizumab in a patient with neovascular glaucoma","volume":"37","author":"KAHOOK MY","year":"2006","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/emm.2006.21","article-title":"Inhibition of corneal neovascularization by rapamycin","volume":"38","author":"KWON YS","year":"2006","journal-title":"Exp Mol Med"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1006\/exer.1999.0790","article-title":"Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization","volume":"70","author":"KVANTA A","year":"2000","journal-title":"Exp Eye Res","ISSN":"https:\/\/id.crossref.org\/issn\/0014-4835","issn-type":"print"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10456-005-3828-3","article-title":"Anti-angiogenic activities of hypericin in vivo: potential for ophthalmologic applications","volume":"8","author":"LAVIE G","year":"2005","journal-title":"Angiogenesis","ISSN":"https:\/\/id.crossref.org\/issn\/0969-6970","issn-type":"print"},{"key":"ref22","author":"LIU Y","year":"2006"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ophtha.2005.10.012","article-title":"Changes in retinal neovascularization after pegaptanib(Macugen) therapy in diabetic individuals","volume":"113","year":"2006","journal-title":"Ophthalmology","ISSN":"https:\/\/id.crossref.org\/issn\/0161-6420","issn-type":"print"},{"key":"ref24","author":"MANZANO R","year":"2006"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.ophtha.2005.02.007","article-title":"Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study","volume":"112","author":"MICHELS S","year":"2005","journal-title":"Ophthalmology","ISSN":"https:\/\/id.crossref.org\/issn\/0161-6420","issn-type":"print"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1006\/exer.2000.0925","article-title":"Expression of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in corneal lymphangiogenesis","volume":"72","author":"MIMURA T","year":"2001","journal-title":"Exp Eye Res","ISSN":"https:\/\/id.crossref.org\/issn\/0014-4835","issn-type":"print"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/01.ico.0000178731.42187.46","article-title":"Prevention and treatment of corneal graft rejection: current practice patterns (2004)","volume":"25","author":"RANDLEMAN JB","year":"2006","journal-title":"Cornea","ISSN":"https:\/\/id.crossref.org\/issn\/0277-3740","issn-type":"print"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1097\/01.ico.0000220768.11778.60","article-title":"Prevention of corneal neovascularization: evaluation of various commercially available compounds in an experimental ratmodel","volume":"25","author":"RIAZI-ESFAHANI M","year":"2006","journal-title":"Cornea","ISSN":"https:\/\/id.crossref.org\/issn\/0277-3740","issn-type":"print"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.ophtha.2005.01.043","article-title":"Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration","volume":"112","author":"ROSENFELD PJ","year":"2005","journal-title":"Ophthalmology","ISSN":"https:\/\/id.crossref.org\/issn\/0161-6420","issn-type":"print"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.ophtha.2006.01.027","article-title":"Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration","volume":"113","author":"ROSENFELD PJ","year":"2006","journal-title":"Ophthalmology","ISSN":"https:\/\/id.crossref.org\/issn\/0161-6420","issn-type":"print"}],"container-title":["Anais da Academia Brasileira de Ci\u00eancias"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/aabc\/v79n3\/a04v79n3.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T10:44:57Z","timestamp":1556880297000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0001-37652007000300004&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["S0001-37652007000300004"],"URL":"https:\/\/doi.org\/10.1590\/s0001-37652007000300004","relation":{},"ISSN":["0001-3765"],"issn-type":[{"value":"0001-3765","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,9]]}}}